Skip to main content

Advertisement

Table 1 HNSCC Patient Characteristics

From: A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Patient characteristics cetuximab (n = 34) % (n) no cetuximab (n = 130) % (n) p value
Male 71% (24) 83% (108) p = 0.10
Female 29% (10) 17% (22)
Mean age [range] 58.8 [35–82] 56.3 [19–80] p = 0.22
Stage at diagnosis
 I, II 12% (4) 9% (12) p = 0.67
 III, IV 88% (30) 90% (117)
 Unknown 0% (0) 1% (1)
HPV status
 Positive 15% (5) 18% (24) p = 0.85
 Negative 26% (9) 26% (34)
 Unknown 59% (20) 52% (70)
Relapsed
 Yes 53% (18) 31% (40) p = 0.043
 No 35% (12) 58% (75)
 Unknown 12% (4) 12% (15)
Received radiation therapy
 Yes 74% (25) 77% (100) p = 0.92
 No 12% (4) 10% (13)
 Unknown 15% (5) 13% (17)
Treatment best response
 Complete response 26% (9) 42% (55) p = 0.004
 Partial response 3% (1) 2% (3)
 Stable disease 3% (1) 1% (1)
 Progressive disease 21% (7) 3% (4)
 Unknown 47% (16) 53% (69)